T ranslational stroke research continues to move ahead, despite several disappointing clinical trial failures in 2012. There are several factors believed to be contributing to the difficulties in translating experimental studies to human stroke, for example, experimental stroke models might vary too significantly from human stroke, there might be biases in some experimental findings, and the pathophysiology of acute brain injury caused by stroke might be different in humans and animals. The current critical assessment of preclinical studies is driving improvement in the quality of experimental studies and expanding the number of hurdles that a molecule must overcome before proceeding to clinical research. In this short overview, we describe selected translational stroke research that has taken place in 2012.
Currently, a candidate drug for successful translation is the postsynaptic density-95 protein (PSD-95) inhibitor, TatNR2B9c, which uncouples postsynaptic density protein PSD-95 from neurotoxic signaling pathways.
1 PSD-95 binds N-methyl-D-aspartate GluN2 subunits and the neuronal NO synthase.
2 Disrupting this complex with PSD-95 inhibitor administered after stroke onset in rodents and nonhuman primate models reduced infarct volume and ameliorated the neurological deficits. 1 Investigation of this therapeutic strategy has followed a process that illustrates bench-to-bed translation on the basis of the preclinical evidence, suggesting beneficial effects. Results of the Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT) phase II trial evaluating the safety and efficacy of Tat-NR2B9c in patients with iatrogenic stroke after endovascular aneurysm repair showed lower stroke incidence in patients assigned to the Tat-NR2B9c group, 3 but larger trials are needed to demonstrate efficacy. Several concepts emerging from experimental findings are now being tested in humans. The notion that coadministration of an adjunctive therapy could augment the value of thrombolytic therapy is attractive but needs validation in the clinic. Several stroke trials combining hypothermia with intravenous thrombolysis are currently underway (eg, ICTuS2/3, EuroHYP-1). The benefits of hypothermia are supported by very robust results in experimental research, 4 but its translation to the clinical setting is logistically challenging. 5 Other ongoing trials test the hypothesis that damping oxidative stress will synergistically augment tissue plasminogen activator treatment. A phase III trial is testing the administration of the natural antioxidant, uric acid, in thrombolyzed patients because of improved outcome and smaller infarctions observed in rodents treated with this combination. 6 Neurons are rapidly lost after stroke, leading to the concept time is brain. 7 Accordingly, neuroprotectant therapies are more effective in animal models when they are administered shortly after stroke onset. This urgency led to the design of trials in the prehospital setting. Results of the large phase III Field Administration of Stroke Therapy -Magnesium (FAST-MAG) stroke trial, in which magnesium sulfate, a compound with antagonistic actions at the N-methyl-D-aspartate receptor, is administered in the ambulance are due to be released in the near future.
Following experimental results demonstrating anti-inflammatory actions of minocycline, 8 the outcome of a phase I stroke clinical trial testing the efficacy of this drug in reducing neurological sequelae is awaited. Increasing experimental evidence supports the relationship among stroke-induced inflammation, the subsequent immune response, and outcome. [9] [10] [11] The deleterious role of complement activation has been shown in experimental stroke models, [12] [13] [14] and complement-induced neuronal cell death after brain ischemia can be prevented by intravenous immunoglobulin. 15 Now a clinical trial (intravenous immunoglobulin/acute ischemic stroke) will test whether immunoglobulin can affect the rate of progression of brain ischemia by scavenging complement fragments. Neuroinflammation and immune responses are tightly related to abnormal function of the blood-brain barrier after brain ischemia, and the involvement of matrix metalloproteinases has been extensively documented. 16, 17 Loss of blood-brain barrier integrity is associated with hemorrhagic transformation, a frequent complication of thrombolysis. Therefore, strategies aimed to prevent bloodbrain barrier leakage deserve future clinical investigation.
Compared with ischemic stroke, there have been less experimental investigations on intracranial hemorrhage, 18 and the molecular and cellular mechanisms underlying hemorrhagic brain damage remain poorly understood. 19 Secondary vasospasm after subarachnoid hemorrhage has been the main target of clinical trials, but failure of antivasospastic drugs to improve the outcome again points to the need for a better understanding of early and delayed brain injury after hemorrhage. 20 Finally, cell therapy, particularly stem cell transplantation, remains an attractive future therapeutic approach. 21, 22 Exciting
Advances in Stroke Translational Medicine 2012
Anna M. Planas, PhD
Planas Planas Advances in Translational Medicine 2012 319
recent experimental findings showed that adult human somatic cells that have been reprogrammed to become induced pluripotent stem cells can form functional neurons and improve recovery after being grafted in a stroke-damaged rodent brain. 23 Many clinical trials administering various types of stem cells to stroke patients are currently ongoing in China, North America, and Europe. Plasticity mechanisms supporting recovery after stroke have been demonstrated in animals after a variety of interventions, 24, 25 and noninvasive imaging techniques are invaluable tools to monitor some of these responses. 26 However, translating restorative therapies from the laboratory to the clinic still faces tremendous challenges. 
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